

Lenvima Approval Status Worldwide (Country/ Region)

April, 2019

Thyroid cancer

Australia	Jan-2016	India	Jan-2017	Poland	May-2015
Austria	May-2015	Indonesia	Jul-2018	Portugal	May-2015
Belgium	May-2015	Ireland	May-2015	Romania	May-2015
Brazil	Aug-2016	Israel	Jan-2016	Russia	Dec-2015
Brunei	Dec-2018	Italy	May-2015	Singapore	Apr-2016
Bulgaria	May-2015	Japan	Mar-2015	Slovakia	May-2015
Cambodia	Apr-2019	Kuwait	May-2016	Slovenia	May-2015
Canada	Dec-2015	Latvia	May-2015	South Korea	Oct-2015
Croatia	May-2015	Lebanon	Nov-2016	Spain	May-2015
Cyprus	May-2015	Liechtenstein	May-2015	Sri Lanka	Feb-2019
Czech Republic	May-2015	Lithuania	May-2015	Sweden	May-2015
Denmark	May-2015	Luxembourg	May-2015	Switzerland	Aug-2015
Estonia	May-2015	Macau	Sep-2015	Taiwan	Sep-2016
Finland	May-2015	Malaysia	Nov-2016	Thailand	Mar-2016
France	May-2015	Malta	May-2015	UAE	Feb-2017
Germany	May-2015	Mexico	May-2016	UK	May-2015
Greece	May-2015	Myanmar	Nov-2018	US	Feb-2015
Hong Kong	May-2016	Netherlands	May-2015		
Hungary	May-2015	Norway	May-2015		
Iceland	May-2015	Philippines	Dec-2016		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

2nd line renal cell carcinoma

Australia	Jul-2017	Israel	Dec-2016	Slovenia	Aug-2016
Austria	Aug-2016	Italy	Aug-2016	Spain	Aug-2016
Belgium	Aug-2016	Latvia	Aug-2016	Sri Lanka	Feb-2019
Brazil	Oct-2018	Lebanon	May-2017	Sweden	Aug-2016
Brunei	Dec-2018	Liechtenstein	Aug-2016	Switzerland	Aug-2017
Bulgaria	Aug-2016	Lithuania	Aug-2016	Taiwan	Jul-2017
Canada	Sep-2017	Luxembourg	Aug-2016	Thailand	Mar-2018
Croatia	Aug-2016	Macau	Jul-2018	UK	Aug-2016
Cyprus	Aug-2016	Malaysia	Oct-2018	US	May-2016
Czech Republic	Aug-2016	Malta	Aug-2016		
Denmark	Aug-2016	Mexico	Jan-2018		
Estonia	Aug-2016	Netherlands	Aug-2016		
Finland	Aug-2016	Norway	Aug-2016		
France	Aug-2016	Philippines	Dec-2016		
Germany	Aug-2016	Poland	Aug-2016		
Greece	Aug-2016	Portugal	Aug-2016		
Hong Kong	Nov-2017	Romania	Aug-2016		
Hungary	Aug-2016	Russia	Sep-2016		
Iceland	Aug-2016	Singapore	May-2017		
Ireland	Aug-2016	Slovakia	Aug-2016		

In Europe, lenvatinib is approved under the brand name Kisplyx[®] for treatment of renal cell carcinoma

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Lenvima Approval Status Worldwide (Country/ Region)

April, 2019

Hepatocellular carcinoma

Australia	Sep-2018	Ireland	Aug-2018	South Korea	Aug-2018
Austria	Aug-2018	Israel	Apr-2019	Spain	Aug-2018
Belgium	Aug-2018	Italy	Aug-2018	Sri Lanka	Feb-2019
Brazil	Feb-2019	Japan	Mar-2018	Sweden	Aug-2018
Bulgaria	Aug-2018	Latvia	Aug-2018	Switzerland	Oct-2018
Canada	Dec-2018	Lebanon	Feb-2019	Taiwan	Nov-2018
China	Sep-2018	Liechtenstein	Aug-2018	UK	Aug-2018
Croatia	Aug-2018	Lithuania	Aug-2018	US	Aug-2018
Cyprus	Aug-2018	Luxembourg	Aug-2018		
Czech Republic	Aug-2018	Malta	Aug-2018		
Denmark	Aug-2018	Netherlands	Aug-2018		
Estonia	Aug-2018	Norway	Aug-2018		
Finland	Aug-2018	Philippines	4mg:Oct-2018		
France	Aug-2018		10mg:Nov-2018		
Germany	Aug-2018	Poland	Aug-2018		
Greece	Aug-2018	Portugal	Aug-2018		
Hong Kong	Feb-2019	Romania	Aug-2018		
Hungary	Aug-2018	Russia	Oct-2018		
Iceland	Aug-2018	Slovakia	Aug-2018		
India	Mar-2019	Slovenia	Aug-2018		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.